ImmunoGen Inc

ImmunoGen — J.P. Morgan Healthcare Conference 2021

24 slides from ImmunoGen's conference presentation, Jan 11, 2021

  1. Slide 1: Target a Better Now

    Slide 1: Target a Better Now

    TARGET A BETTER NOW Nasdaq: IMGN J.P. Morgan Healthcare Conference January 11-14, 2021 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    2 This presentation includes forward-looking statements regarding ImmunoGen’s expectations related to the design and potential success of ImmunoGen’s mirvetuximab soravtansine and IMGN632 clinical studies and regulatory pathways, including the timing of initiating and receiving data from, as well as

  3. Slide 3: Why ImmunoGen?

    Slide 3: Why ImmunoGen?

    3 POISED TO BECOME A FULLY - INTEGRATED ONCOLOGY COMPANY WITH TWO PRODUCTS ON THE MARKET BY THE END OF 2022 ACCELERATED PATH FOR MIRVETUXIMAB IN PROC PIVOTAL DATA: Q3 2021 POTENTIAL APPROVAL: 2022 INNOVATIVE EARLIER STAGE CANDIDATES AND ADVANCED ADC TECHNOLOGY ANTICIPATED COMPENDIA LISTINGS FOR MIRV

  4. Slide 4: Strategic Priorities

    Slide 4: Strategic Priorities

    4 BRINGING ANTIBODY - DRUG CONJUGATES TO CANCER PATIENTS STRATEGIC PRIORITIES F U R T H E R STRENGTHEN BALANCE SHEET AND EXPAND CAPABILITIES T H R O U G H PARTNERSHIPS ADVANCE PORTFOLIO OF EARLIER STAGE PRODUCT CANDIDATES WITH A FOCUS ON PATH TO FULL APPROVAL FOR I M G N 6 3 2 C O M P L E T E MIRVET

  5. Slide 5: Someone you know has been diagnosed with ovarian cancer

    Slide 5: Someone you know has been diagnosed with ovarian cancer

    SOMEONE YOU KNOW HAS BEEN DIAGNOSED WITH OVARIAN CANCER … WHAT’S NEXT FOR HER? 5

  6. Slide 6: Urgent Need in Ovarian Cancer

    Slide 6: Urgent Need in Ovarian Cancer

    U R G E N T NEED 1NIH SEER Data: Estimated New Cases, 2020 2JCO: Vol 33, No. 32, Nov 2015. 3Gyn Onc: Vol 133 (2014) 624-631. PFS: progression-free survival; PARPi: poly ADP-ribose polymerase inhibitor; BEV: AVASTIN® (bevacizumab) OVARIAN CANCER IS THE LEADING CAUSE OF DEATH FROM GYNECOLOGICAL CANCER

  7. Slide 7: Mirvetuximab Soravtansine

    Slide 7: Mirvetuximab Soravtansine

    MIRVETUXIMAB SORAVTANSINE 7 DESIGNED TO DISPLACE CHEMOTHERAPY TO DELIVER MORE GOOD DAYS FOR WOMEN WITH OVARIAN CANCER KEY ATTRIBUTES • Novel ADC with distinct FRα-binding antibody, cleavable linker, and maytansinoid DM4 payload • Favorable tolerability profile • Demonstrated activity in patients wit

  8. Slide 8: Aligned with FDA Recommendations

    Slide 8: Aligned with FDA Recommendations

    8 ALIGNED WITH FDA RECOMMENDATIONS Women with FRα-high platinum- resistant ovarian cancer that has progressed after prior treatment with bevacizumab require better therapeutic options MIRVETUXIMAB: POTENTIAL FOR ACCELERATED APPROVAL SUPPORTING DATA POOLED POST-HOC ANALYSIS FROM PHASE 1 AND PHASE 3 F

  9. Slide 9: Single-Arm Pivotal Trial SORAYA

    Slide 9: Single-Arm Pivotal Trial SORAYA

    9 SINGLE-ARM PIVOTAL TRIAL FOR MIRVETUXIMAB IN FRα-HIGH PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER PRIMARY ENDPOINT ORR by Investigator BICR for Sensitivity Analysis SECONDARY ENDPOINT DOR by Investigator ENROLLING GLOBALLY TARGET TIMELINES ENROLLMENT AND KEY ELIGIBILITY ~110 patients Platinum-

  10. Slide 10: Phase 3 Randomized Trial MIRASOL

    Slide 10: Phase 3 Randomized Trial MIRASOL

    10 Mirvetuximab PHASE 3 RANDOMIZED TRIAL FOR MIRVETUXIMAB IN FRα-HIGH PATIENTS WITH PLATINUM- RESISTANT OVARIAN CANCER PRIMARY ENDPOINT PFS by Investigator BICR for Sensitivity Analysis *Eligibility criterion different than SORAYA sBLA: Supplemental Biologics License Application; IC: investigator’s

  11. Slide 11: Evaluating Combinations for Label Expansion

    Slide 11: Evaluating Combinations for Label Expansion

    11 1ASCO 2019 Poster; O’Malley, D., et al. 2ASCO 2020 Oral Presentation; Gilbert, L., et al. 3Gynecologic Oncology 151 (2018) 46-52. 4ESMO 2020 Poster; O’Malley, D., et al. mPFS: median progression-free survival EVALUATING COMBINATIONS FOR POTENTIAL LABEL EXPANSION WHILE GENERATING DATA TO SUPPORT C

  12. Slide 12: Mirvetuximab Market Opportunity

    Slide 12: Mirvetuximab Market Opportunity

    12 MIRVETUXIMAB MARKET OPPORTUNITY ADDRESSING KEY SEGMENTS OF THE RECURRENT OVARIAN CANCER MARKET ~40% OF OVARIAN CANCER PATIENTS ARE FRα-HIGH EXPRESSORS MONOTHERAPY Bevacizumab Pre-Treated 2L-4L Platinum-Resistant TOP-LINE RESULTS Q3 2021 ~2,100 FRα -HIGH PATIENTS FORWARD II MIRV + CARBO COMBINATIO

  13. Slide 13: Robust Data in More Than 700 Patients

    Slide 13: Robust Data in More Than 700 Patients

    13 ROBUST DATA IN MORE THAN 700 PATIENTS • Strong and consistent efficacy data in FRα-high patients • Favorable tolerability profile • Selection assay identifies patients most likely to benefit SORAYA: POTENTIAL PATH TO ACCELERATED APPROVAL • Enrolling patients globally • Top-line data expected in Q

  14. Slide 14: Someone you know has been diagnosed with BPDCN

    Slide 14: Someone you know has been diagnosed with BPDCN

    SOMEONE YOU KNOW HAS BEEN DIAGNOSED W I T H B P D C N … WHAT’S NEXT? 14

  15. Slide 15: BPDCN Outcomes Remain Poor

    Slide 15: BPDCN Outcomes Remain Poor

    15 OUTCOMES REMAIN POOR, PARTICULARLY FOR NON- TRANSPLANT CANDIDATES CURRENTLY APPROVED THERAPIES REQUIRE INPATIENT HOSPITALIZATION AND ARE ASSOCIATED WITH SIGNIFICANT TOXICITIES B P D C N I S A RARE AND AGGRESSIVE HEMATOLOGIC MALIGNANCY ~500-1,000 NEW CASES DIAGNOSED ANNUALLY IN THE US1 60% TO 70%

  16. Slide 16: IMGN632

    Slide 16: IMGN632

    IMGN632 16 1ASH 2018 Oral Presentation; Daver, N., et al. ASH 2019 Oral Presentation; Daver, N., et al. 2ASH 2020 Oral Presentation; Pemmaraju, N., et al. AML: acute myeloid leukemia; MRD+: minimal residual disease positive; ALL: acute lymphocytic leukemia DESIGNED TO TARGET MULTIPLE CD123+ HEMATOLO

  17. Slide 17: IMGN632 Safety, Efficacy and FDA Alignment

    Slide 17: IMGN632 Safety, Efficacy and FDA Alignment

    17 FAVORABLE SAFETY PROFILE • No capillary leak syndrome • No drug-related discontinuations • No drug-related deaths • Limited grade ≥3 TEAEs EFFICACY In all R/R BPDCN patients: • ORR: 29% (8/28, 2 CR, 2 CRc, 1 CRi, 3 PR) • CCR: 18% (5/28) In patients with prior tagraxofusp exposure: • ORR: 31% (4/1

  18. Slide 18: Single-Arm Pivotal Cohort in Frontline BPDCN

    Slide 18: Single-Arm Pivotal Cohort in Frontline BPDCN

    18 SINGLE-ARM PIVOTAL COHORT FOR IMGN632 IN FRONTLINE BPDCN PRIMARY ENDPOINT CR plus CRc SECONDARY ENDPOINT Duration of CR/CRc ENROLLING IN THE US AND EU TARGET TIMELINES ENROLLMENT AND KEY ELIGIBILITY Up to 20 frontline patients Includes patients with prior local therapy Patients ≥18 years old CD12

  19. Slide 19: IMGN632 in AML Combinations

    Slide 19: IMGN632 in AML Combinations

    19 1ASH 2020 Poster; Kuruvilla, V., et al. VEN: venetoclax; AZA: azacitidine EVALUATING COMBINATION DOUBLET AND TRIPLET REGIMENS OF IMGN632 PLUS AZACITIDINE AND/OR VENETOCLAX PRE- CLINICAL COMBINATION DATA 1 • IMGN632+VEN+AZA triplet significantly improved survival compared to VEN+AZA doublet in CD1

  20. Slide 20: Advancing Earlier Stage Candidates: IMGC936

    Slide 20: Advancing Earlier Stage Candidates: IMGC936

    20 ADVANCING OUR PORTFOLIO OF EARLIER STAGE PRODUCT CANDIDATES 20 1AACR 2019 Poster; Hicks S., et al. ADAM: a disintegrin and metalloproteinase • First-in-class ADAM9-targeting therapy • ADAM9 is overexpressed in multiple solid tumors (e.g., non-small cell lung, gastric, pancreatic, triple- negative

  21. Slide 21: Advancing Earlier Stage Candidates: IMGN151

    Slide 21: Advancing Earlier Stage Candidates: IMGN151

    21 21 1AACR 2020 Poster; Ab, O., et al. IND: investigational new drug application • Next-generation anti-FRα ADC designed to have improved activity against tumors with a broad range of FRα-expression (e.g., ovarian, endometrial, triple-negative breast, and non-small cell lung cancer)1 • Comprised of

  22. Slide 22: Our Approach to Partnering

    Slide 22: Our Approach to Partnering

    OUR APPROACH TO PARTNERING MAXIMIZE THE VALUE OF OUR STRATEGIC PROGRAMS BY RISK SHARING AND PARTNERING FOR CAPABILITIES 22 MACROGENICS Development and commercialization of mirvetuximab in Greater China Global co-development and co-commercialization of IMGC936 OUT-LICENSING Key legacy licenses enable

  23. Slide 23: Our Path to Becoming a Fully-Integrated Oncology Company

    Slide 23: Our Path to Becoming a Fully-Integrated Oncology Company

    23 OUR PATH TO BECOMING A FULLY-INTEGRATED ONCOLOGY COMPANY MIRVETUXIMAB • Complete enrollment in pivotal SORAYA trial • Share top-line SORAYA data in Q3 2021 and submit BLA by end of 2021 • Present mature MIRV + BEV data in recurrent ovarian cancer at ASCO 2021 • Support initiation of neoadjuvant a

  24. Slide 24: Important Catalysts in 2021

    Slide 24: Important Catalysts in 2021

    TARGET A BETTER NOW IMPORTANT CATALYSTS IN 2021 FOR LEAD MIRVETUXIMAB PROGRAM PIVOTAL DATA IN Q3 AND BLA BY YEAR-END INNOVATIVE EARLIER STAGE CANDIDATES IN SOLID TUMORS IMGC936: FIRST-IN-CLASS ADAM9-TARGETING ADC IN THE CLINIC IMGN151: NEXT-GENERATION FRα-TARGETING ADC IND EXPECTED BY YEAR-END LEADI

Source: SEC EDGAR · 8-K filed Jan 11, 2021

More decks from ImmunoGen Inc